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Abstract
Engineered biomatrices offer the potential to recapitulate the regenerative microenvironment, with important
implications in tissue repair. In this context, investigation of the molecular interactions occurring between growth
factors, cytokines and extracellular matrix (ECM) has gained increasing interest. Here, we sought to investigate the
possible interactions between the ECM proteins fibronectin (FN) and fibrinogen (Fg) with the CXCR3 ligands CXCL9,
CXCL10 and CXCL11, which are expressed during wound healing. New binding interactions were observed and
characterized. Heparin-binding domains within Fg (residues 15-66 of the β chain, Fg β15-66) and FN (FNI1-5, but not
FNIII12-14) were involved in binding to CXCL10 and CXCL11 but not CXCL9. To investigate a possible influence of
FN and Fg interactions with CXCL11 in mediating its role during re-epithelialization, we investigated human
keratinocyte migration in vitro and wound healing in vivo in diabetic db/db mice. A synergistic effect on CXCL11-
induced keratinocyte migration was observed when cells were treated with CXCL11 in combination with FN in a
transmigration assay. Moreover, wound healing was enhanced in full thickness excisional wounds treated with fibrin
matrices functionalized with FN and containing CXCL11. These findings highlight the importance of the interactions
occurring between cytokines and ECM and point to design concepts to develop functional matrices for regenerative
medicine.
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Introduction
Regenerative medicine has evolved from an initial focus on
transplanted cells to also embrace development of advanced
biomatrices laden with active biomolecules that enhance tissue
repair and control the host response by mimicking the
regenerative microenvironment[1,2]. In this context, a full
comprehension of the overall signaling network driving wound
healing is still missing and the complex pattern of interactions
between the different biological moieties involved (i.e.
cytokines, growth factors, extracellular matrix (ECM) proteins,
integrin ligands) is incompletely understood. Still, new insights
into the pivotal interactions regulating dermal wound healing
can have important implications for new therapies, such as in
treatment of diabetic foot ulcers.
Skin wound healing is the result of a complex network of
biological events where the ECM and other soluble molecules
such as growth factors and cytokines play a fundamental role
in driving the fate of different cell types. Recently, an important
role has become clear for the ELR-negative cytokines CXCL10
and CXCL11, signaling through their common receptor
CXCR3, in coordinating the regenerative and resolving phase
of cutaneous healing[3]. Delivery of a CXCL11 antisense
construct worsened wound healing, leading to delayed re-
epithelialization and impaired epidermis maturation, a
phenotype observed in CXCR3-deficient mice as well[4-6].
Although a full understanding of the biological processes
linking the CXCR3 axis to wound healing is still missing, it is
now clear that CXCL11, expressed in injured epidermis, plays
an important role in enhancing undifferentiated keratinocyte
motility, thus coordinating the resolution and regenerative
phase together with signals coming from the ECM [3,7].
Recently, the importance of the ECM in presenting growth
factors during the regenerative phase of wound healing has
gained interest, particularly in view of development of new
biomatrices for morphogen delivery[8,9]. Interactions between
ECM proteins and morphogens modulate local morphogen
concentration and signaling and can create specific
biomolecular gradients based on the ECM composition. Good
examples are the interactions between fibroblast growth
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factor-2 (FGF-2), transforming growth factor beta (TGF-β) and
vascular endothelial growth factor-A (VEGF-A) with
proteoglycans as well as ECM proteins vitronectin, fibrin and
FN[10-15]. Heparin binding domains of different ECM proteins
have been shown to bind certain growth factors. In recent
studies, our laboratory has shown rather promiscuous growth
factor interactions with the 12th-14th type III repeats of
fibronectin (FNIII 12-14)[10], residues 15-66 of the β chain of
fibrinogen (Fg β15-66)[16] and the 5th fibronectin-like repeat of
tenascin C[17]. Such interactions were engineered to develop
biomatrices for tissue repair through presentation of growth
factors such as VEGF-A and PDGF-BB [9,16].
Here, we sought to investigate potential interactions
occurring between two of the most important matrix proteins,
FN and Fg, and CXCR3 ligands expressed in injured
epidermis, CXCL9, CXCL10 and CXCL11[18]. Discovering
such binding with CXCL10 and CXCL11, we turned our
attention to the effects of these interactions both in vitro and in
vivo in the context of the role of CXCL11 in modulating
keratinocyte migration and coordinating re-epithelialization. We
show that the interaction of CXCL11 with FN can be exploited
in fibrin matrices to enhance wound healing in the db/db
diabetic mouse.
Results
Fibronectin and fibrinogen bind CXCL10 and CXCL11,
but not CXCL9
We first investigated the ability of FN and Fg to bind CXCL9,
CXCL10 and CXCL11, using an indirect ELISA. PDGF-BB was
used as positive control due to its high affinity binding to both of
these ECM molecules [10,16], while binding to bovine serum
albumin (BSA) was measured as negative reference control.
Briefly, the cytokines were coated on ELISA plates, blocked
and subsequently incubated with either FN or Fg. Binding was
evaluated by using a specific antibody against either FN or Fg
and normalized to binding on adsorbed PDGF-BB. Since weak
binders of FN such as PDGF-CC and VEGF-C were previously
reported to bind FN with a relative binding to PDGF-BB close to
0.05 we define this value as threshold to define relevant
binders [10]. CXCL10 and CXCL11 were both observed to bind
FN and Fg, while CXCL9 was not (Figure 1). Binding to other
cytokines from the CC chemokine, interferon and interleukin
families was also investigated. Among interleukins, only IL-2
and IL-4 weakly bound to FN (Figure S1), and IL-1α was the
only interleukin showing a positive signal when tested for Fg
binding (Figure S2). Among the members of interferon family,
IFN-γ showed binding to both FN and Fg with high affinity,
while IFN-β was only a weak binder of Fg (Figure S1, Figure
S2). In the CCL family, CCL-20 showed a low level of binding
to FN (Figure S1). Importantly, since our group previously
reported no differences in coating efficiencies between growth
factors coming from the same family[10,16], the lack of signal
shown by some cytokines likely was not related to poor coating
efficiency on the ELISA plate.
FNI 1-5 and Fg β15-66 are involved in binding of
fibronectin and fibrinogen to CXCL10 and CXCL11
Since heparin-binding domains of FN and Fg have already
been described as promiscuous growth factor binding domains
Figure 1.  Fibronectin and fibrinogen binding to CXCL9, CXCL10 and CXCL11.  CXCL9, CXCL10 and CXCL11 binding to FN
(A) and Fg (B) was determined by indirect ELISA and calibrated to PDGF-BB binding to FN as a strongly binding reference (Abs
450nm = 0.59 AU) and Fg (Abs 450 nm=0.79 AU), respectively. FN and Fg binding to BSA were considered as background and
subtracted. Binding of CXCL10 and CXCL11, but not CXCL9, was observed (*). (n=6, mean ± SD).
doi: 10.1371/journal.pone.0079610.g001
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involved in interactions between ECM molecules and
morphogens [9,16,17], we sought to investigate the possible
role of their possible role in binding to CXCL10 and CXCL11.
FNIII 12-14, the 1st-5th type I repeats of FN (FNI 1-5) and the
residues Fg β15-66 were recombinantly produced and tested
for binding to cytokines. While the tested cytokines did not bind
to FNIII 12-14 (data not shown), they showed a significant
affinity to FNI 1-5 and Fg β15-66 by indirect ELISA (Figure 2),
with BSA being used as negative control. To better evaluate
the affinity of binding to both of these heparin-binding domains,
the equilibrium binding constants (Kd) were determined by
ELISA as described elsewhere[19]. In general, Fg β15-66 was
able to bind the two cytokines with higher affinity than FNI 1-5.
Indeed, Kd values of 67 and 68 nM were observed for the
binding of Fg β15-66 to CXCL11, CXCL10, respectively. Higher
Kd values of 136 nM and 752 nM were observed for binding of
FNI 1-5 to the same cytokines (Figure 3). Student’s t-test was
performed in order to confirm FNI 1-5 and Fg β15-66 binding.
CXCL10 and CXCL11 binding to FNI 1-5 and Fg β15-66
is inhibited by heparin
To investigate the possible role of heparin in regulating
cytokine binding, the same indirect ELISA method described
above was performed in presence of different heparin
concentrations (2 nM-20 μM). CXCL10 and CXCL11 binding to
FNI 1-5 and Fg β15-66 was inhibited by the presence of
heparin at low and high concentrations (Figure 4). In general,
heparin reduced binding to both ECM domains, and a high
excess of heparin, at 2 μM, essentially blocked the binding of
the cytokines to the evaluated heparin binding domains (Figure
4).
CXCL11-induced keratinocyte migration is enhanced in
presence of fibronectin
Since CXCL11 has an important role during re-
epithelialization by coordinating keratinocyte migration, we
sought to investigate whether the interactions between
CXCL11, FN and Fg could modulate this biological process in
vitro. HeCaT cells (immortalized human keratinocytes)
transmigration towards CXCL11 in the presence of either FN or
Fg was analyzed by a modified Boyden chamber
transmigration assay (Figure 5A). Briefly, HeCaT cells were
seeded in the upper chamber and the number of cells
transmigrating towards the testing medium contained in the
lower chamber was monitored during the time of the
experiment. In general, CXCL11-driven keratinocyte migration
was strongly enhanced when CXCL11 was presented to the
cells together with FN, especially in the first 6 hr (Figure 5B,
5C). The presence of Fg together with CXCL11 did not
enhance keratinocyte migration compared to cells migrating
towards CXCL11 alone (Figure 5B, 5C). Curve interpolation
analysis was also performed to investigate the speed of
migration during the first 6 hr. The highest speed of migration
was detected when cells were migrating towards CXCL11/FN,
at 240 ± 15 cells/hr compared to 73 ± 21 cells/hr observed
when cells were migrating towards CXCL11 alone (Figure 5D),
thus highlighting a possible role of FN in coordinating
keratinocytes migration by properly presenting CXCL11 to the
cells. FN alone did not enhanced keratinocyte transmigration or
migration speed (Figure 5B, 5C, 5D). To test whether and
which integrins were involved in the enhancement of
keratinocyte migration observed when CXCL11 was presented
to the cells together with FN, we blocked α5β1 and αVβ3 by
using specific antibodies (Figure 5E). α5β1 and αVβ3 were
chosen because they are two major receptors of FN. In the first
6 hr, blocking α5β1 and αVβ3 integrins did not affect
keratinocyte migration towards CXCL11 alone, however
blocking α5β1 integrin when CXCL11 was presented together
with FN decreased keratinocyte migration to the level observed
for migration in response to CXCL11 alone. αVβ3 blocking did
not affect keratinocyte migration towards CXCL11 presented
on FN. Statistical analysis by using a one-way ANOVA with
Figure 2.  FNI 1-5 and Fg β15-66 binding.  FNI 1-5 and Fg β15-66 binding to CXCL10 and CXCL11 was determined by indirect
ELISA. ELISA plates were coated with either CXCL10 or CXCL11 and probed with either FNI 1-5 (black bars) (A) or Fg β15-66
(black bars) (B). Binding to BSA was measured as negative control (white bars) (n=3, mean ± SD, Student’s t-test, *p<0.001).
doi: 10.1371/journal.pone.0079610.g002
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Dunnett’s comparison to Control was performed and
demonstrated the significance indicated above.
Co-delivery of CXCL11 and fibronectin enhances
wound repair in diabetic mice
The enhancement of keratinocyte migration observed in the
presence of CXCL11 with FN encouraged us to explore
whether their co-delivery could enhance skin wound healing in
vivo. Diabetic db/db mice, a genetic mouse model of type-2
diabetic mellitus, were used a as well established and widely
used experimental model of delayed wound healing. Full-
thickness excisional skin wounds were treated with fibrin
functionalized with FN and containing CXCL11. Four different
groups (n=8) were tested: fibrin only, fibrin containing CXCL11,
fibrin functionalized with FN and fibrin functionalized with FN
and containing CXCL11. The wounds were harvested after 10
d, and histological analysis was performed to analyze wound
closure and granulation tissue formation. As statistical analysis,
one-way ANOVA with Dunnett’s comparison to the fibrin group
was performed.
As shown in Figure 6, despite a moderate acceleration in
wound closure, no statistically significant differences in
granulation tissue formation were observed when wounds were
treated with either fibrin functionalized with FN or fibrin
containing CXCL11 compared to fibrin only-treated wounds. In
contrast, delivery of CXCL11 in FN-functionalized fibrin led to a
further increase in reepithelialization and to a two-fold higher
amount of granulation tissue development (Figure 6). Indeed,
high or complete (75% - 100%) wound closure by the 10th day
was observed only in wounds treated with FN-functionalized
fibrin containing CXCL11, while all the other treatments led to
partial (25% - 75%) or almost absent (0% - 25%) wound
closure. As expected, fibrin only treatment led to the least
granulation tissue formation and slowest re-epithelialization.
Figure 3.  KD analysis.  KD was determined by indirect ELISA. ELISA plates were coated with CXCL10 (A, B) or CXCL11 (C, D) and
probed with increasing concentrations (25 nM-3.2 μM) of either FNI 1-5 (A, C) or Fg β15-66 (B, D) in the absence of heparin.
Binding to BSA was considered as background and subtracted (n=3, mean).
doi: 10.1371/journal.pone.0079610.g003
CXCL11 and Fibronectin Interactions
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Immunohistochemical analysis for cytokeratin 16, a marker
expressed by hyper-proliferating keratinocytes after wounding,
further highlighted the differences in re-epithelialization due to
the different treatments (Figure 7) and showed the tips of
migrating epithelial tongues (Figure S3). Since both CXCR3
ligands and FN are important mediators in recruiting immune
cells at sites of inflammation and since macrophages are
important mediators of wound healing, we evaluated the
presence of monocytes/macrophages in the granulation tissue
by immunohistochemical analysis for CD68. Although we
observed a higher amount of granulation tissue formation in
wounds treated with FN-functionalized fibrin containing
CXCL11 (Figure 6), no increased monocyte/macrophage
infiltration was observed compared to wounds treated with
either FN-functionalized or CXCL11-containing fibrin gels
(Figure S3).
Discussion
Our group has previously investigated growth factor binding
to FN[9,10] and Fg[16]. We have reported that binding of a
growth factor to FN can modulate its signaling for the cases of
vascular endothelial growth factor-A (VEGF-A), platelet-derived
growth factor-BB (PDGF-BB) and bone morphogenetic
protein-2 (BMP-2)[9]. Here, we turned our attention to
chemokine-ECM interactions, and we show that CXCL10 and
CXCL11, but not CXCL9, bind to FN and Fg, and further that
FN but not Fg binding modulates CXCL11's biological activity
toward keratinocyte migration. The interactions between
CXCL11 and FN is particularly interesting in the context of
wound healing, due to the role of CXCL11 in coordinating re-
epithelialization[5,7] and to the importance of FN in controlling
both cell migration through integrin signaling and growth factor
partitioning, diffusion and signaling[9,20,21]. Here we showed
that the effects of CXCL11 on in vitro keratinocyte migration
and re-epithelialization in vivo are enhanced in the presence of
Figure 4.  Heparin competition analysis.  ELISA plates were coated with CXCL10 (A, B) or CXCL11 (C, D) and probed with FNI
1-5 (A, C) or Fg β15-66 (B, D) in the presence of increasing concentrations of heparin (2 nM - 20 μM). Binding was related to the
binding observed in the absence of heparin. Binding to BSA was considered as background and subtracted. (n=3, mean±SD).
doi: 10.1371/journal.pone.0079610.g004
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FN, highlighting the importance of investigating the interactions
between soluble morphogens (both growth factors and
cytokines) and ECM molecules to both elucidate biological
function in the physiological context and develop new
biomatrices for regenerative medicine applications.
Indeed, an emerging interest in cytokine delivery to mediate
wound healing has grown in the last few years due to a better
understanding of the complex integration of signals derived
from the immune system and the regenerative
microenvironment[2,22]. Although interactions between
heparan sulfate glycosaminoglycans and several cytokines
have been investigated[23,24], cytokine binding to protein
components of the provisional matrix deposited during wound
healing has been poorly investigated. We here sought to
identify potential new interactions between CXCR3 ligands (i.e.
CXCL9, CXCL10 and CXCL11) and two of the most important
proteins of the provisional matrix deposited during tissue repair,
FN and Fg. These two molecules were selected because of
their clear role in acting as a reservoir for heparin-binding
growth factors and in coordinating wound healing. Thus, we
found that CXCL10 and CXCL11 bound to both FN and Fg
(Figure 1), in addition to other immune regulators, especially
IFN-γ (Figures S1 and S2).
To better investigate the nature of the observed interactions,
we then examined whether CXCL10 and CXCL11 bind the
heparin binding domains of FN and Fg. Although FNIII 12-14 is
a promiscuous growth factor binding domain, we observed no
binding between it and CXCL10 or CXCL11, thus suggesting
the involvement of another FN domain in the interactions. To
this point, we found that CXCL10 and CXCL11 bound to the N-
Figure 5.  Keratinocyte migration towards CXCL11.  In vitro keratinocyte migration was evaluated by a modified Boyden
chamber transmigration assay. HeCaT cells were stained with Vybrant® DIO cell tracer and seeded in the upper chamber. The
number of cells transmigrating towards the test medium contained in the lower chamber was monitored during the time of the
experiment by live imaging microscopy (A). Transmigration was quantified through automatic cell identification and cell counting
within 12 hr. Solid lines show the number of migrating cells. Dashed lines show segmented interpolation analysis of the curves. (B).
Number of transmigrated HeCaT cells (C) and transmigration speed (D) during the first 6 hr of the assay. (E) Number of
transmigrated HeCaT cells in presence of blocking antibodies for α5β1 and αvβ3 integrins. (n=6, mean ± SD, One-way ANOVA with
Dunnett’s comparison to Control, ** p<0.01, *** p<0.001).
doi: 10.1371/journal.pone.0079610.g005
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terminal heparin binding domain of FN (FNI 1-5) as well as to
the heparin binding domain of Fg (Fg β15-66) with affinities (Kd)
in the nanomolar range (Figure 3), comparable with the
affinities previously reported for growth factor binding to FNIII
12-14 and Fg β15-66[10,16]. We then showed that the
presence of heparin decreased binding to both FNI 1-5 and Fg
Figure 6.  Wound healing in db/db mice.  CXCL11 enhances wound healing when delivered in FN-functionalized fibrin matrices.
Wound closure and granulation tissue formation was evaluated in full-thickness excisional skin wounds in diabetic db/db mice.
Wound edges (black arrows) and tips of migrating epithelial tongues (red arrows) are indicated. (Representative images, n=8, mean
± SD, One-way ANOVA with Dunnett’s comparison to Fibrin group, * p<0.05, *** p<0.001).
doi: 10.1371/journal.pone.0079610.g006
Figure 7.  Cytokeratin 16 expression.  Immunohistochemical analysis for cytokeratin 16 highlights hyper-proliferating
keratinocytes in migrating epithelial tongues. Wound edges (black arrows) and tips of migrating epithelial tongues (red arrows) are
indicated. Higher resolution images of epithelial tongue tips are shown in Figure S3. (Representative images, n=8, mean ± SD, One-
way ANOVA with Dunnett’s comparison to Fibrin group, * p<0.05, *** p<0.001).
doi: 10.1371/journal.pone.0079610.g007
CXCL11 and Fibronectin Interactions
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β15-66 (Figure 4), an opposite effect compared to the one
observed for growth factor binding to FN[25,26]. These
observations highlight the complexity and the differences
between cytokine and growth factor binding to FN and Fg and
suggest a possible role for specific molecular structures in
mediating binding to ECM.
As was observed to be the case for growth factor binding to
Fg β15-66[16], the presence of a heparin binding domain within
the cytokines was necessary, but not sufficient, to provide
binding to both FNI 1-5 and Fg β15-66. Indeed, among the
three tested CXCR3 ligands, only CXCL10 and CXCL11 bound
FN and Fg, while they all bind heparin with different
affinities[27-30]. CXCL9 has an extended highly positively
charged C-terminus, compared to CXCL10 and CXCL11, which
might be the responsible for the different binding behavior.
Indeed, CXCL9 presents 27 and 30 extra amino acid residues
at the C-terminus compared to CXCL10 and CXCL11,
respectively, which have a short and highly similar C-terminal
residues after Cys74, a conserved cysteine residue involved in
a disulfide bond. Interestingly, the presence of cleavage sites
for gelatinase B and neutrophil collagenase within this
extended region[31] could suggest a possible change of
CXCL9 binding properties following C-terminal cleavage.
However, further studies are needed, and the nature of
cytokine-ECM interactions will be likely understood in the future
only by crystallographic analysis of the different complexes.
Since binding of FN to VEGF-A, PDGF-BB and BMP-2 was
observed in previous studies from our laboratory to modulate
the function of these growth factors [9], we turned our attention
to the biological implications of FN and Fg binding to CXCL11.
In particular, binding of CXCL11 to FN might be important
during wound healing and re-epithelialization, where both
molecules coordinate keratinocyte migration during tissue
repair. FN can be crosslinked to fibrin within the provisional
matrix by the coagulation transglutaminase factor XIIIa, and it
is considered an important molecule in driving keratinocyte
migration through several integrins, including α5β1, αvβ1 and
αvβ6[32,33]. CXCL11 is produced by keratinocytes in response
to damage and regulates re-epithelialization by enhancing their
motility[6,7].
Here, we found that FN but not Fg binding modulates
CXCL11's effects on keratinocyte migration in a transmigration
in vitro assay, CXCL11-induced migration being strongly
enhanced in the presence of FN. Blocking α5β1 integrin when
CXCL11 was presented together with FN, but not αvβ3,
decreased keratinocyte migration to the level observed for
CXCL11 alone, suggesting involvement of this integrin in
enhancing keratinocyte migration. The existence of an
allosteric network among FNI 1-5, FNIII 12-14 and FNIII 9-10,
the major α5β1 binding site of FN, together with recent findings
showing that ligation of FNIII 10 increases accessibility of FNI
1-5 [34], suggest that the physical proximity of CXCR3 and
α5β1 might be important for mediating induced keratinocyte
migration. Notably, the absence of an allosteric network
between Fg β15-66 and α5β1 binding sites in Fg [35] might
explain the inability of Fg binding to CXCL11 in modulating
CXLC11 activity.
To evaluate the biological effects of FN binding in vivo, we
used a full-thickness excisional wound model in db/db diabetic
mice, a model commonly used during preclinical evaluation of
therapeutics for chronic wound healing[9]. A significant
enhancement of granulation tissue formation together with
faster wound re-epithelialization and closure were observed in
wounds treated with FN-functionalized fibrin matrices
containing CXCL11, thus confirming an important role of FN
and CXCL11 interactions in coordinating re-epithelialization
and wound healing. Although our results suggest that binding
to FN within the provisional matrix enhances re-epithelialization
by enhancing keratinocyte migration, further experiments
aiming at the study of the initial phases of wound healing are
needed to better explore the effects of these interactions on
granulation tissue formation. Indeed, despite increased
granulation tissue formation in wounds treated with FN-
functionalized fibrin gels containing CXCL11, the presence of
monocyte/macrophages in the granulation tissue was not
influenced by CXCL11 binding to FN, suggesting that binding
does not likely influence granulation tissue composition.
However, since CXCR3 ligands are important mediators in
recruiting immune cells at inflammation sites[36] we can
hypothesize that binding to FN might influence the initial stages
of wound healing, potentially favoring both a broad immune cell
infiltration and keratinocyte migration.
Although CXCR3 ligands have been previously reported as
important mediators of re-epithelialization[5,7], their use as
therapeutic molecules in wound healing is, to our knowledge,
unexplored. Our results indicate that they are potentially
interesting molecules as therapeutic candidates, at least when
the biomolecular interactions in the tissue or biomatrix
microenvironment are well considered. More generally, our
results highlight that better knowledge of the interactions
occurring between growth factors, cytokines and the ECM will
yield design rules by which appropriate partitioning and
presentation of these important therapeutic molecules can be
recreated.
Materials and Methods
Ethics statement
All animal procedures and manipulations were conducted
according to the ethical principles and guidelines for housing
and experiments on animals of the Swiss federal veterinary
office. The animal protocol describing the procedures was
reviewed and approved by the veterinary affair office of the
canton of Vaud, Switzerland.
Cytokines, FNI 1-5 and Fg β15-66
All cytokines were purchased highly pure, carrier free and
lyophilized from PeproTech EC Ltd. All cytokines were
reconstituted and stored according to the manufacturer’s
instructions. Full length FN from human plasma was purchased
from Sigma-Aldrich. Human Fg depleted from plasminogen,
vWF and fibronectin was purchased from MILAN Analytica AG.
FNIII 12-14 and Fg β15-66 were produced and purified as
previously described[10,16]. FNI 1-5 (residues P51 to H273)
was expressed in mammalian cells, HEK-293E, using the
CXCL11 and Fibronectin Interactions
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vector pXLG, which uses an IgK leader sequence for secretion
of the FN fragment. NotI and BamHI restriction sites were used
to clone the construct in frame. At the C-terminus of the
construct is a short linker sequence, LE, followed by a 6×His
tag sequence. HEK-293E cells were transfected with 1.25 μg of
plasmid per 105 cells per 1 mL of final growth medium (Excell
293, 4 mM glutamine, 3.75 mM valproic acid). The culture
medium was harvested after 7 d of shaker flask expression and
cells were removed by filtration. The protein was then purified
using an FPLC (Akta Explorer, GE Healthcare) with a HisTrap
HP column (GE Healthcare). The lipopolysaccharide (LPS)
levels were detected with a HEK-BlueTM LPS Detection Kit
(InvivoGen) to ensure no LPS presence in the fragments.
Detection of cytokine binding to ECM molecules
ELISA plates (Nunc MaxiSorp; Thermo Fisher Scientific)
were coated with 50 nM cytokines (overnight at 4°C) and
blocked with 2% BSA in PBS-Tween 20 (PBS-T, 0.05%) for 1 h
at room temperature. Then, wells were washed with PBS-T and
further incubated with of FN (10 nM), Fg (10 nM), FNI 1-5 (100
nM) or Fg β15-66 (100 nM), 30 min in PBS-T with 0.1% BSA).
After 3 washes with PBS-T, wells were incubated with anti-FN
(clone 5G7, Abcam), anti-Fg (Ab7539, Abcam) or anti-6xHis
antibody conjugated to horseradish peroxidase accordingly to
the tested molecule for 0.5–1 h. After washing, the antibody
was detected with tetramethylbenzidine substrate
measurement of the absorbance at 450 nm. Binding of FN, Fg,
FN I1-5 and Fg β15-66 to BSA and binding of anti-FN, anti-Fg
and anti-6xHis antibodies to the tested cytokines were
considered as background and thus properly subtracted from
binding results. PDGF-BB was used as positive binding control
and absorbances were calibrated accordingly.
Heparin competition assay
Indirect ELISA was performed as described above, probing
with either FNI 1-5 or Fg β15-66 in presence of different
concentrations (2 nM - 20μM) of heparin (Sigma-Aldrich).
Kd analysis
ELISA plates (Nunc MaxiSorp; Thermo Fisher Scientific)
were coated with 20 nM CXCL10, 20 nM CXCL11 or 50 nM
IFN-γ (overnight at 4°C) and blocked with 2% BSA in PBS-
Tween 20 (PBS-T, 0.05%) for 1 h at room temperature. Then,
wells were washed with PBS-T and further incubated with
increasing concentrations (25 nM - 3.2 μM) of either FNI 1-5 or
Fg β15-66 for 30 min in PBS-T with 0.1% BSA). After 3 washes
with PBS-T, wells were incubated with anti-6xHis antibody
conjugated to horseradish peroxidase for 0.5–1 h. After
washing, the antibody was detected with tetramethylbenzidine
substrate measurement of the absorbance at 450 nm. Binding
to BSA-coated wells was used as control and the absorbance
subtracted from the aborbance obtained from cytokines-coated
wells. Kd were then calculated by linearization of the curves as
described elsewhere[19].
Modified-Boyden chamber transmigration assay and
time lapse image analysis
Chemotaxis was studied by real time transwell migration
assay using 8 μm-pore inserts (BD Falcon Fluoroblok) in a 24-
well plate format. HeCaT cells, adherent in a cell culture flask,
were stained with 4 μl/mL of Vybrant® DIO cell tracer (Life
Technologies Corp.) in serum free medium. After washing
extensively with complete medium, cells were detached with
accutase (Biological Industries), resuspended in serum free
DMEM or with blocking antibodies for either α5β1 (Abcam
clone J8S5, 1μg/ml or αvβ3 (Abcam clone 23C6, 1μg/ml) and
then placed in the top chamber of the inserts (1 x 106 cells in
150 μl). Equimolar concentrations of CXCL11 (0.2 μg/ml), FN
(5 μg/ml) and Fg (7 μg/ml) were added in the bottom chamber
accordingly to the experiment in 700 μl of serum free DMEM
per insert. The plates were sealed, connected to 5% CO2-Air
mix, placed at 37°C in the Cell IQ MLF® live imaging
microscope (CM Technologies Oy, Tampere, Finland) and
fluorescence images of the lower side of the insert membranes
were acquired for 12 h at 15 min intervals using a 10x
objective. Transmigration was quantified through automatic cell
identification and cell counting using the CellIQ Analyser®
software (CM Technologies, Tampere, Finland). Segmented
interpolation analysis was performed to investigate the speed
of migration during the first 6 hr.
Full-thickness excisional skin wound model
C57BLKS/J-m/Lepr db (db/db) male mice were 10 to 12 wk
old at the start of the experiments. Their backs were shaved
and four full-thickness punch biopsy wounds (6 mm in
diameter) were created in each mouse. Directly after, fibrin
matrices [80 μl total, fibrinogen (10 mg/ml), 0.5 μM FN, 50 ng
murine CXCL11] were polymerized on the wounds. To avoid
animal- and position-dependency each animal was treated with
the four tested fibrin matrices in randomized positions. To avoid
drying of the matrices, the wounds were covered with non-
adhering dressing (Adaptic, Johnson & Johnson) and then with
adhesive film dressing (Hydrofilm, Hartmann). After 10 d the
animals were sacrificed and the wounds were harvested for
histological analysis. An area of 10 mm in diameter, which
includes the complete epithelial margins, was excised. Wounds
were cut in the middle and embedded. Histological analysis
was performed on serial sections (4-μm paraffin sections)
starting from the central part of the wound. Wound closure and
granulation tissue formation were measured by
histomorphometric analysis of tissue sections (hematoxylin and
eosin stain) by using ImageJ software. Wound edges were
defined by the position of the panniculus carnosus edges and
by the morphology of unwounded epidermis. Wound closure
was defined by looking at tips of migrating epithelial tongue and
by measuring the percentage of the wound that was covered
with new epidermis. Granulation tissue area was defined as the
area of highly cellularized tissue observed within the wound
bed.
Immunohistemical analysis
Paraffin-embedded tissue sections were dewaxed,
rehydrated and endogenous peroxidase quenched with 3%
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H2O2 solution in PBS. A antigen retrieval step at 95°C for 20
min in 10 mM Tris-Citrate buffer was performed before blocking
with 2% BSA solution in PBS for 1 hr. Sections were then
incubated overnight at 4°C with primary antibodies against
either Cytokeratin 16 (Abcam ab53117, 1:200 in 2% BSA
solution in PBS) or CD68 (Abcam ab125212, 1:100 in 2% BSA
solution in PBS). HRP-conjugated secondary anti-rabbit
antibody (Dako) and SIGMAFASTTM DAB (Sigma-Aldrich) were
used.
Supporting Information
Figure S1.  Fibronectin binds cytokines from different
families. Binding to FN was determined by indirect ELISA and
calibrated to PDGF-BB binding as a strongly binding reference
(Abs 450nm = 0.59 AU). FN binding to BSA was considered as
background and subtracted. Binding of IL-2, IL-4, IFN-γ, CCL20
was observed (*). (n=6, mean ± SD).
(TIF)
Figure S2.  Fibrinogen binds cytokines from different
families. Binding to Fg was determined by indirect ELISA and
calibrated to PDGF-BB binding as a strongly binding reference
(Abs 450nm = 0.79 AU). Fg binding to BSA was considered as
background and subtracted. Binding of IL-1α, IFN-β and IFN-γ
was observed (*). (n=6, mean ± SD).
(TIF)
Figure S3.  Cytokeratin 16 and CD68 immunohistochemical
analysis. Cytokeratin 16 and CD68 positive cells were
detected by immunohistochemical analysis with DAB staining
and Meyer’s hematoxylin counterstaining. High magnification
representative images of the tips of migrating epithelial cells
(cytokeratin 16) and granulation tissue (CD68) are shown.
(Scale bars, 100 μm).
(TIF)
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